MAIA Expands Phase 2 Trial for NSCLC Treatment into U.S. with First Site Activation

Event summary

  • MAIA Biotechnology activated its first U.S. clinical site for the Phase 2 THIO-101 expansion trial targeting advanced non-small cell lung cancer (NSCLC).
  • The trial, funded by a $2.3 million NIH grant, will evaluate ateganosine as a third-line treatment for NSCLC patients resistant to chemotherapy and checkpoint inhibitors.
  • MAIA plans to open four additional U.S. sites in 2026, expanding the trial's reach beyond its current 44 international sites in Europe and Asia.
  • THIO-101 has shown exceptional efficacy data, including overall survival beyond two years for eight patients treated with ateganosine sequenced with cemiplimab.

The big picture

MAIA's expansion into the U.S. marks a critical step in validating its novel telomere-targeting approach for NSCLC, a market with significant unmet needs. The trial's progress will be closely watched as it competes with existing checkpoint inhibitors and other emerging therapies. Success could position ateganosine as a best-in-class treatment for heavily pre-treated NSCLC patients.

What we're watching

Trial Execution
The pace at which MAIA can enroll patients and open additional U.S. sites will determine the trial's timeline and potential for accelerated FDA review.
Regulatory Pathway
Whether the FDA Fast Track designation will expedite ateganosine's review process and potentially lead to accelerated approval.
Competitive Positioning
How ateganosine's dual mechanism of action and immune-activating properties will differentiate it in the crowded NSCLC treatment landscape.